Last reviewed · How we verify
Ruxolitinib Oral Tablet [Jakafi] — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ruxolitinib Oral Tablet [Jakafi] (Ruxolitinib Oral Tablet [Jakafi]) — Oncotherapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ruxolitinib Oral Tablet [Jakafi] TARGET | Ruxolitinib Oral Tablet [Jakafi] | Oncotherapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ruxolitinib Oral Tablet [Jakafi] CI watch — RSS
- Ruxolitinib Oral Tablet [Jakafi] CI watch — Atom
- Ruxolitinib Oral Tablet [Jakafi] CI watch — JSON
- Ruxolitinib Oral Tablet [Jakafi] alone — RSS
Cite this brief
Drug Landscape (2026). Ruxolitinib Oral Tablet [Jakafi] — Competitive Intelligence Brief. https://druglandscape.com/ci/ruxolitinib-oral-tablet-jakafi. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab